Data / Form D filings / Supreme Pharmaceuticals Inc.
Supreme Pharmaceuticals Inc.: Form D filings
Supreme Pharmaceuticals Inc., a pharmaceuticals company in Toronto, Ontario, Canada, filed 6 Form D notices with the SEC between 2014 and 2017. The latest, on March 17, 2017, reports $369,667 sold of a $369,667 offering to 1 investor.
Find out what Supreme Pharmaceuticals Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 202 - 20 De Boers Drive, Toronto, Ontario, Canada, M3J 0
- Phone
- (647) 525-5463
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- British Columbia, Canada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1622240
The full lists. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 17, 2017 | New notice | $369,667 | $369,667 | $0 | 1 | Dec 13, 2016 | sec.gov |
| May 8, 2015 | New notice | $1,212,649 | $1,212,649 | $0 | 27 | Apr 23, 2015 | sec.gov |
| Feb 3, 2015 | New notice | $116,985 | $116,985 | $0 | 3 | Jan 23, 2015 | sec.gov |
| Nov 20, 2014 | New notice | $149,117 | $149,117 | $0 | 5 | Sep 19, 2014 | sec.gov |
| Nov 10, 2014 | New notice | $538,049 | $538,049 | $0 | 12 | Nov 5, 2014 | sec.gov |
| Oct 20, 2014 | New notice | $525,800 | $525,800 | $0 | 7 | Sep 19, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Scott Walters | Director | |
| Chuck Rifici | Director | |
| Navdeep Dhaliwal | Executive Officer, Director | |
| John Fowler | Executive Officer, Director | |
| Michael La Brier | Director |
Every Form D from the week of Mar 13, 2017 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Supreme Pharmaceuticals Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.